These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 9220317)

  • 1. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
    Kim CJ; Prevette T; Cormier J; Overwijk W; Roden M; Restifo NP; Rosenberg SA; Marincola FM
    J Immunother; 1997 Jul; 20(4):276-86. PubMed ID: 9220317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity.
    Kim CJ; Cormier J; Roden M; Gritz L; Mazzara GP; Fetsch P; Hijazi Y; Lee KH; Rosenberg SA; Marincola FM
    Ann Surg Oncol; 1998; 5(1):64-76. PubMed ID: 9524710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
    J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.
    Abdel-Wahab Z; Kalady MF; Emani S; Onaitis MW; Abdel-Wahab OI; Cisco R; Wheless L; Cheng TY; Tyler DS; Pruitt SK
    Cell Immunol; 2003 Aug; 224(2):86-97. PubMed ID: 14609574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
    van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
    Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.
    Butterfield LH; Jilani SM; Chakraborty NG; Bui LA; Ribas A; Dissette VB; Lau R; Gamradt SC; Glaspy JA; McBride WH; Mukherji B; Economou JS
    J Immunol; 1998 Nov; 161(10):5607-13. PubMed ID: 9820539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells.
    Motta I; André F; Lim A; Tartaglia J; Cox WI; Zitvogel L; Angevin E; Kourilsky P
    J Immunol; 2001 Aug; 167(3):1795-802. PubMed ID: 11466405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
    Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
    J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
    Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
    J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.
    Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG
    J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.
    Fleischhauer K; Tanzarella S; Wallny HJ; Bordignon C; Traversari C
    J Immunol; 1996 Jul; 157(2):787-97. PubMed ID: 8752930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
    Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
    Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen.
    Labarrière N; Bretaudeau L; Gervois N; Bodinier M; Bougras G; Diez E; Lang F; Gregoire M; Jotereau F
    Int J Cancer; 2002 Sep; 101(3):280-6. PubMed ID: 12209980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes.
    Liao X; Li Y; Bonini C; Nair S; Gilboa E; Greenberg PD; Yee C
    Mol Ther; 2004 May; 9(5):757-64. PubMed ID: 15120337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma.
    Philip R; Alters SE; Brunette E; Ashton J; Gadea J; Yau J; Lebkowski J; Philip M
    J Immunother; 2000 Jan; 23(1):168-76. PubMed ID: 10687150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.